2023
Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer
McNamara B, Chang Y, Mutlu L, Harold J, Santin A. Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer. Expert Opinion On Biological Therapy 2023, 23: 227-233. PMID: 36800548, DOI: 10.1080/14712598.2023.2182679.Peer-Reviewed Original ResearchConceptsUse of pembrolizumabCervical cancerStandard chemotherapyMetastatic PD-L1Recurrent cervical cancerMetastatic cervical cancerNon-expressing tumorsVEGF therapyPD-L1Clinical efficacyGlobal morbidityPharmacologic propertiesChemotherapyPembrolizumabBevacizumabCancerRecurrentTreatmentTolerabilityFurther benefitImmunotherapyContraindicationsMorbidityEvidencePatients
2022
In Silico Analysis of the Multi-Targeted Mode of Action of Ivermectin and Related Compounds
Aminpour M, Cannariato M, Preto J, Safaeeardebili M, Moracchiato A, Doria D, Donato F, Zizzi E, Deriu M, Scheim D, Santin A, Tuszynski J. In Silico Analysis of the Multi-Targeted Mode of Action of Ivermectin and Related Compounds. Computation 2022, 10: 51. DOI: 10.3390/computation10040051.Peer-Reviewed Original ResearchAnti-inflammatory pathwaySARS-CoV-2 virusAlpha 7 nicotinic acetylcholine receptorCholinergic anti-inflammatory pathwayAnti-viral effectsActivity of ivermectinNicotinic acetylcholine receptorsBiological mechanismsVagus nerveCytokine productionImmune cellsClinical studiesCD147 receptorViral penetrationAcetylcholine receptorsNeuronal tissueIvermectinMolecular targetsHigh affinitySpike glycoproteinPhysiological concentrationsMorbidityCOVID-19VirusReceptors